Tsubota Laboratory Incorporated (JP:4890)
:4890
Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥210.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥5.62B
Enterprise Value¥5.68B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥85.26M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.97
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and substantial equity provide a durable financial cushion that supports operations during revenue volatility. Over the next 2–6 months this conservatism reduces refinancing risk and gives management flexibility to fund R&D or commercial activity without immediate capital raises.
High Gross MarginA roughly 66% gross margin indicates favorable product economics at the unit level. This margin strength supports potential margin recovery once fixed costs are reduced or volumes normalize, enabling profitability to improve faster than top-line recovery in a multi-month timeframe.
Proven Ability To Return To ProfitPrior multi-year profitability and a 2025 rebound demonstrate operational capability and market demand under the right conditions. This track record suggests the business model can generate profits again, reducing structural risk over the medium term if management executes cost control and commercialization plans.
Bears Say
Severe Revenue DeclineAn 85% YoY revenue drop is a structural red flag: it erodes scale, weakens pricing leverage, and magnifies fixed-cost strain. Recovery typically requires product/regulatory fixes or new commercial traction, creating substantial execution risk and reduced cash generation over the next several months.
Persistent Negative Operating Cash FlowSustained operating cash deficits deplete liquidity and increase reliance on external funding. Even with low debt, continued cash burn pressures capital allocation, may force dilution or debt financing, and limits ability to invest in R&D or commercialization over the 2–6 month horizon.
Extreme Earnings VolatilitySharp swings from profitable years to deep losses indicate unstable revenue streams or concentration risk. Such volatility complicates planning, increases cost of capital, and raises the probability that operational fixes will be required before sustainable profitability can be restored.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥5.62B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Aug 07, 2026 which is in 54 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on May 14, 2026. The company reported -¥9.38 earnings per share for the quarter, missing the consensus estimate of N/A by -¥9.38.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥9.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.375%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―